Login to Your Account



Orphan Drug For Treatment Failures

Savient Travels Gout Route; Phase III Results Due Shortly

By Randall Osborne


Monday, October 22, 2007
As a therapeutic indication, rheumatoid arthritis gets more love from investors, but another painful joint disorder has come to the fore as well, and Savient Pharmaceuticals Inc. is the company they talk about when they talk about gout. (BioWorld Financial Watch)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription